ArticleEBioMedicine2026
Nasal RNA-scaffold-protein vaccine protects mice from human H5N1 clade 2.3.4.4b virus lethal infection and safeguards against vaccine-unmatched viruses.
Article in EBioMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecent cases of H5N1 avian influenza spilling over into human populations have raised concerns once again about the unpredictable emergence of zoonotic viral diseases. This phenomenon highlights the persistent threat posed by viruses that jump from animals to humans, underscoring the need for preparedness for antigens that humans have not encountered. Nasal vaccines, which can effectively block transmission at the site of viral entry, represent a promising strategy and should be prioritised for stockpiling to halt zoonotic spillover.
methodsHere, we immunised a preclinical animal model intranasally with the RNA-Scaffold-Protein Vaccine (RSPVac) and evaluated mucosal immunity and protection against avian-origin and pandemic human influenza viruses.
findingsNasal immunisation of strain-specific H5N1 and H1N1 RSPVac induced strong antibody responses in serum and mucosa, accompanied by mucosal antigen-specific T cells. We examined immune cells during early vaccination and found that RSPVac induced a strong but transient cytokine expression. Neutrophils comprising both regulatory and effector subsets were observed, indicating a controlled activation. Vaccinated animals were completely protected against vaccine-matched avian virus challenges without pathological signs. Protection was also observed against vaccine-unmatched H1N1 and H7N9 challenges, with a display of trained immune cell profiles. Finally, mutant RSPVac demonstrated an impaired vaccination outcome, suggesting a complex activation mechanism.
interpretationThese findings demonstrate that RSPVac elicits potent mucosal immunity and safeguards against vaccine-unmatched infections, underscoring its potential as a non-infectious mucosal vaccine to prevent zoonotic virus transmission.
fundingThis study is supported by the Health@InnoHK initiative of the Innovation and Technology Commission of the Hong Kong Special Administrative Region Government.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.